Mario Niepel

Ribon Therapeutics (United States)

Full Professor(heuristic)

PARP inhibition in cancer therapy · Oncology

h-index36

i10-index44

Publications104

Citations7,016

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 9 of 9

Data from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
Supplementary Figures 1 - 4 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
Supplementary Figure Legend and Tables 2 - 3 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
Supplementary Table 1 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
2023-03-30
Supplementary Table 1 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
2023-03-30
Supplementary Figure Legend and Tables 2 - 3 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
Supplementary Figures 1 - 4 from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
Data from Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPreprint
2023-03-30
ADP‐ribosyltransferases, an update on function and nomenclature
FEBS Journal · 2021-07-29 · 328 citations

Open author page on OpenAlex →